This report deals with 120 cadaveric renal transplants performed in 10
1 pediatric recipients in this Centre in two five-year periods, 1984 t
o 1988 (N = 65) and 1989 to 1993 (N = 55). In the first group transpla
nts were allocated on the basis of best size (small donors for small r
ecipients); in the second group priority was given to beneficial HLA m
atching. Initial immunosuppression was either cyclosporine (CsA) monot
herapy (15 mg/kg/day), or triple therapy (CsA 5 mg/kg/day, prednisolon
e 1 mg/kg/day and azathioprine 1 mg/kg/day) if there was delayed graft
function. Patient survival at one year and five years (97.5% and 92.3
%, respectively) did not differ between the two groups, although there
was an improvement in graft survival at one and five years in the sec
ond period relative to the first: 69.2% and 53.8% versus 78.6% and 65.
6%. This did not achieve statistical significance. One year graft surv
ival in recipients under five years did not differ significantly from
older children (72%). There was a trend to improvement in one year gra
ft survival in the < five years of age pediatric patients in Group 2,
with beneficially matched kidneys and improved immunosuppressive manag
ement. Graft losses due to acute rejection were similar in both groups
. Donor age < 4 years significantly reduced one year graft survival (6
3% vs. 85%, P = 0.01), while recipient age had no effect. Small donor
kidneys were associated with a higher incidence of graft thrombosis. T
ransplantation resulted in the normalization or acceleration of growth
velocity in (84%) of the pre-pubertal children who completed follow u
p. In conclusion, we have shown that excellent patient and graft survi
val can be achieved in children transplanted under the age of five yea
rs. Kidneys from donors under the age of four years are associated wit
h an unacceptable rate of graft loss. Small children do not readily ac
cept cyclosporine monotherapy. Successful early renal transplantation
offers the best chance of normal growth and development.